StockData

Exozymes Inc. (EXOZ) stock

EXOZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 5/30
$3.31−0.68 (-17.04%)

Close on Nov 17, 2026Market cap $30.72MP/E –Yield –

Exozymes operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Exozymes's operating cash flow for the twelve months ending Sep 30, 2026 was -$7.36M. For fiscal 2025 it was -$6.50M.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$6.50M–
FY2024Dec 31, 2024-$8.51M–
FY2023Dec 31, 2023-$1.18M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$2.22M–
Q2 FY2026Jun 30, 2026-$1.64M–
Q1 FY2026Mar 31, 2026-$1.52M–
Q4 FY2025Dec 31, 2025-$1.97M–
Q3 FY2025Sep 30, 2025-$1.86M–
Q2 FY2025Jun 30, 2025-$1.54M–
Q1 FY2025Mar 31, 2025-$1.13M-503.1%
Q4 FY2024Dec 31, 2024-$5.71M–
Q3 FY2024Sep 30, 2024-$541.52K–
Q2 FY2024Jun 30, 2024-$2.54M–
Q1 FY2024Mar 31, 2024$281.20K–
Q4 FY2023Dec 31, 2023-$783.28K–

More Exozymes figures

See a number that looks wrong?